u. k. m h r ray r a regulatory agency is using these antibody level protection as a proxy for a wider clinical studies. and again, this is just tweaking the original vaccine. so others a lot of confidence that there isn't going to be a significant difference in side effect profiles. i with however, being useful for winter when we see lots of other research re, viruses, also circulating putting pressure and health system. yeah. and, and just on that with the northern hemisphere, winter, just around the corner. how significant and how needed is this vaccine at this point in time? well, certainly this is being welcomed by many governments. however, the e u vs the case to gain bit more of a conscious approach, waiting for more a clinical data before they approve, unless there is a, an as significant turn of events. however, what we could see is that a new form of variance said start to become dominant in the winter, which means that to we will need to continue developing vaccines in future. this certainly isn't going to be the last of the, this type of cove. it next generation vaccines. what we probably w